Watch for the engagement of a new auditor and the timely filing of the Q3 2026 10-Q. Failure to file on time or a further delay in auditor engagement could trigger Nasdaq listing issues and further erode investor confidence.
Price Chart
Executive Summary
Shuttle Pharmaceuticals dismissed its auditor, Forvis Mazars, effective after the Q3 2026 10-Q filing. The dismissal follows previously disclosed material weaknesses in internal controls and a going-concern qualification, and the company has not yet engaged a replacement auditor. This creates uncertainty around the company's financial reporting and compliance timeline.
Key Facts
- Forvis Mazars, LLP dismissed as independent auditor effective after Q3 2026 10-Q filing.
- No new auditor has been engaged as of the filing date.
- Prior audit reports (FY 2024, 2025) included a going-concern explanatory paragraph.
- Multiple material weaknesses in internal controls were previously disclosed and remain unremediated.
- No disagreements on accounting principles or audit scope were reported.
- Forvis Mazars agreed with the company's statements in the filing.
Financial Impact
No specific financial impact quantified in the filing. The auditor dismissal and unremediated material weaknesses increase the risk of a late filing, potential Nasdaq non-compliance, and higher audit costs.
Risk Factors
- Delayed filing of Q3 2026 10-Q due to lack of auditor.
- Potential Nasdaq delisting if filing obligations are not met.
- Going-concern risk already flagged; auditor departure may exacerbate financing difficulties.
- Unremediated material weaknesses increase risk of financial misstatement.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-048112 |
| Exhibit: ex16-1.htm | 0001493152-26-048112 |
| Document: 0001493152-26-048112-index-headers.html | 0001493152-26-048112 |
| Document: 0001493152-26-048112-index.html | 0001493152-26-048112 |
| Document: 0001493152-26-048112.txt | 0001493152-26-048112 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $4.86 $5.05 | ▼ −3.81% | ▼ −3.10% | $5.05 (−3.81%) |
Sep 1, 2026 7w ago | 8-K | $3.49 $3.48 | ▼ −0.29% | ▼ −1.33% | $5.05 (+44.56%) |
Jul 13, 2026 15w ago | 3 | $2.96 $4.16 | ▲ +40.54% | ▲ +40.19% | $5.05 (+70.44%) |
Jul 1, 2026 16w ago | 3 | $3.58 $3.50 | ▼ −2.23% | ▼ −3.11% | $5.05 (+40.92%) |
Jun 11, 2026 19w ago | 8-K | $3.91 $3.76 | ▼ −3.84% | ▼ −5.60% | $5.05 (+29.03%) |
May 7, 2026 24w ago | 8-K | $6.89 $6.79 | ▲ +1.45% | ▲ +1.68% | $5.05 (+26.78%) |
May 1, 2026 25w ago | 8-K | $6.92 $8.27 | ▼ −19.51% | ▼ −19.88% | $5.05 (+27.10%) |
Mar 10, 2026 32w ago | 8-K | $0.9010 $0.9260 | ▲ +2.77% | ▲ +4.26% | $5.05 (+459.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers